• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024

    4/10/24 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TXG alert in real time by email

    PLEASANTON, Calif., April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

    10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)

    Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.

    About 10x Genomics

    10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

    Disclosure Information

    10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

    Contacts 

    Investors: [email protected] 

    Media: [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-report-first-quarter-2024-financial-results-on-april-30-2024-302113577.html

    SOURCE 10x Genomics, Inc

    Get the next $TXG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TXG

    DatePrice TargetRatingAnalyst
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    9/3/2024$35.00Outperform
    Leerink Partners
    7/22/2024$24.00Hold → Buy
    Jefferies
    7/18/2024$40.00 → $20.00Overweight → Neutral
    JP Morgan
    7/10/2024$55.00 → $25.00Buy → Hold
    Deutsche Bank
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/25/2024Buy → Neutral
    Guggenheim
    6/3/2024$24.00Hold
    Jefferies
    More analyst ratings